Astellas to shut 3 labs as part of R&D restructuring

05/15/2013 | Genetic Engineering & Biotechnology News

Astellas Pharma plans to revamp its research and development unit by closing U.S. laboratories in Redwood City, Calif., and Farmingdale, N.Y., this year, and another laboratory in Japan in 2015. Some of the laboratories' work will be transferred to the firm's Tsukuba Research Center in Japan. Astellas also plans to refocus its Skokie, Ill., research institute as an R&D site for central nervous system drugs.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Regulatory Lawyer EMEA (f/m)
W. L. Gore & Associates GmbH
Putzbrunn (near Munich)
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA